Mydecine Innovations Group Inc.
MYCOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.05 | 0.00 | -0.00 |
| FCF Yield | 0.00% | -4.08% | 4.08% | -24.07% |
| EV / EBITDA | 130.35 | 56.97 | -45.74 | 2.48 |
| Quality | ||||
| ROIC | -0.94% | 3.28% | 4.56% | -25.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | -0.03 | -0.02 | -0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -200.96% | 115.89% | -228.52% |
| Safety | ||||
| Net Debt / EBITDA | 130.16 | 55.12 | -44.27 | 2.40 |
| Interest Coverage | 0.00 | -1.94 | -2.66 | 5.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |